Psychological health in central hypersomnias: The French Harmony study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 6, 2009, Pages 636-641

  Dauvilliers, Y ^a,b   Paquereau, J ^c   Bastuji, H ^d   Drouot, X ^e   Weil, J S ^f   Viot Blanc, V ^f,g  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b INSERM   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Cephalon France   (France)

^g HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; MAZINDOL; MODAFINIL; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ANTIDEPRESSANT AGENT; BENZHYDRYL DERIVATIVE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BECK DEPRESSION INVENTORY; BODY MASS; CATAPLEXY; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; FEMALE; HLA TYPING; HUMAN; HYPERSOMNIA; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SEX DIFFERENCE; SLEEP PATTERN; TREATMENT RESPONSE; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; PATIENT SATISFACTION; PERSONALITY TEST; SOMNOLENCE;

ADULT; ANTIDEPRESSIVE AGENTS; BENZHYDRYL COMPOUNDS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; DEPRESSION; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERSOMNOLENCE, IDIOPATHIC; MALE; MIDDLE AGED; NARCOLEPSY; PATIENT SATISFACTION; PERSONALITY INVENTORY; POLYSOMNOGRAPHY; QUALITY OF LIFE;

EID: 66149124880     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.161588     Document Type: Article

References (35)

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369:499-511. (Pubitemid 46209316)
2. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep 1994;17:45-49
3. Vignatelli L, D'Alessandro R, Mosconi P, et al. Health-related QoL in Italian patients with narcolepsy: the SF-36 health survey. Sleep Med 2004;5:467-475 (Pubitemid 39194057)
4. Daniels E, King MA, Smith IE, et al. Health-related QoL in narcolepsy. J Sleep Res 2001;10:75-81.
5. AASM. The International Classification of Sleep Disorders, 2nd Edn, revised. Diagnostic and Coding Manual. Chicago, IL: American Academy of Sleep Medecine, 2005.
6. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-997
7. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002;59:1553-1562
8. Dauvilliers Y, Baumann CR, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003;74:1667-1673 (Pubitemid 37542057)
9. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003;54:96-104. (Pubitemid 36859768)
10. Roth B, Nevsimalova S. Depresssion in narcolepsy and hypersomnia. Schweiz Arch Neurol Neurochir Psychiatr 1975;116:291-300.
11. Mosko S, Zetin M, Glen S, et al. Self-reported depressive symptomatology, mood ratings, and treatment outcome in sleep disorders patients. J Clin Psychol 1989;45:51-60. (Pubitemid 19061240)
12. Merritt S, Cohen F, Smith K. Depressive symptomatology in narcolepsy. Loss Grief Care 1992;5:53-59
13. Bassetti C, Aldrich MS. Idiopathic hypersomnia. A series of 42 patients. Brain 1997;120:1423-1435 (Pubitemid 27344709)
14. Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev 2001;5:349-358 (Pubitemid 33089566)
15. Carskadon MA, Mitler MM, Roth T. Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep 1986;9:519-524 (Pubitemid 17131209)
16. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545
17. Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57:2029-2033 (Pubitemid 33126870)
18. Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. Psychol Rep 1974;34:1184-1186
19. Bennett DS, Ambrosini PJ, Bianchi M, et al. Relationship of Beck Depression Inventory factors to depression among adolescents. J Affect Disord 1997;45:127-134 (Pubitemid 27373690)
20. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
21. Ware JE Jr, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International QoL Assessment. J Clin Epidemiol 1998;51:1167-1170 (Pubitemid 28527172)
22. Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003;114:2000-2017 (Pubitemid 37298050)
23. Silber MH, Krahn LE, Olson EJ, et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002;15:197-202.
24. Mignot E, Lin L, Finn L, et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006;129:1609-1623 (Pubitemid 43999391)
25. Singh M, Drake CL, Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006;29:890-895
26. Heier MS, Evsiukova T, Vilming S, et al. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007;30:969-973 (Pubitemid 47221896)
27. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev 2005;9:231-241 (Pubitemid 40982495)
28. Ervik S, Abdelnoor M, Heier MS, et al. Health-related QoL in narcolepsy. Acta Neurol Scand 2006;114:198-204.
29. Szklo-Coxe M, Young T, Finn L, et al. Depression: relationships to SP and other sleep disturbances in a community sample. J Sleep Res 2007;16:297-312. (Pubitemid 47283925)
30. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97.
31. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
32. Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on QoL in narcolepsy. Sleep 2006;29:1189-1194 (Pubitemid 44484812)
33. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related QoL effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-765 (Pubitemid 29445343)
34. Taneja I, Haman K, Shelton RC, et al. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol 2007;27:76-79 (Pubitemid 46105770)
35. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-1249 (Pubitemid 47292414)